Porphyria Educational Services |
|
ABOUT THIS UNSAFE DRUG LISTING: The pharmaceutical listing contained herein has been devised without reference to language, societal, cultural, dietary, prescribing or dispensing conditions [including those imposed by law], other than those of the United States, which might affect the information provided. This list of pharmaceuticals contains only the listing of drugs known to be UNSAFE or considered potentially to be UNSAFE for porphyrics. Listing of the pharmaceuticals on this site are due to the actions,precautions, side effects, or interactions of the given medication in relation to porphyria patients, or the drug's action in regard to cytochrome P-450 and it's metabolism in the liver. The listing of these pharmaceuticals is not intended as medical advice for individual problems. It is provided only for porphyria patients making an evaluation as to the risks and benefits of taking a particular drug. The potential for various drugs triggering attacks of acute porphyria is based primarily on clinical evidence. Some conclusions are based upon tests with animals with experimental porphyria. The information about drugs contained in this database is general in nature and is intended for use as an educational aid. It also does not cover all possible uses of a said medicine. *Be reminded that a specific drugs may work well for one porphyria patient and not for another usually due to other existing medical conditions of the particular patient. Porphyria patients and their physicians must make their decisions on the use of medications appropriate to their own circumstances and in view of other existing medical conditions. The following unsafe drug list must serve only as a guide since individual patient reactions to specific drug is complex and unpredictable especially with other existing conditions both related and unrelated to the various porphyrias. Because many new drugs have not been tested, such drugs should be avoided. It often takes up to five years to realize the side effects of many new drugs on the market. If it is critical that an untested drug be used, contact with a porphyria specialist should be made before proceeding to use the drug in question. Drugs marked with an asterisk * have been documented as associated with acute attacks of porphyria. Information on this website is for the use of Porphyria Patients and their Physicians only and may not be sold. CITATIONS: APF American Porphyria Foundation, Houston, Texas Dr. Douglas E. Geoger, Ph.D. AU Dr. Michael Moore M.D. University of Queensland, Brisbane, Australia CAN Dr. Barry Tobe, M.D. Canadian Porphyria Foundation, Canada FR French Center for the Porphyrias, Paris France GD Dr. H. Winter Griffith MD Guide to Drugs P-450 Dr. David Flockhardt, Pharmacology, Indiana University Medical School SA University of Cape Town Medical Research Council - Liver Research Center - South Africa NE The Netherlands Unsafe Drug List (Rene Gessel) OH Dr. Thomas DeLoughery MD, Oregon Heaklth Sciences University, Portland, Oregon UK United Kingdom Porphyria Drug Index WU Washington University Medical School, St. Louis, Missouri Individual pharmaceutical packing information enclosures. * Indicates that there is evidence that the drug has induced porphyria. |